Gujarat Themis Biosyn completes acquisition of MicroBiopharm Japan Co.

In September 2026, Gujarat Themis Biosyn Limited completed the acquisition of 100% of Japan-based MicroBiopharm Japan Co., Ltd. for JPY 21.5 billion, marking a major step in its push to build a globally integrated, fermentation-based CDMO business. The acquisition, first announced on May 22, 2026, was completed through Themis Biosyn Japan Limited, GTBL’s wholly owned Japanese subsidiary, following receipt of customary regulatory approvals and fulfilment of closing conditions.

GTBL acquired MBJ from funds managed or advised by T Capital Partners Co., Ltd., a Japan-based private equity fund. The transaction was funded through a mix of debt and equity and is expected to be earnings-per-share accretive for GTBL. MBJ’s existing management team will continue to run the business. With more than six decades of operating experience, MBJ runs three GMP-compliant manufacturing facilities and has a track record of inspections by the US Food and Drug Administration (FDA) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA).

Dr. Sachin Patel, Managing Director, GTBL, also said that the acquisition marks a significant milestone in GTBL’s strategy to build a fermentation-based, globally integrated CDMO. He highlighted MicroBiopharm’s more than six decades of fermentation expertise, proprietary P450 enzyme platform and long-standing relationships with global pharmaceutical companies. According to Patel, the combined capabilities will support GTBL’s expansion across areas such as oncology, immunosuppressants, peptides and advanced biologics. Meanwhile, Shiota, CEO of MicroBiopharm Japan, said the acquisition will combine MicroBiopharm’s precision fermentation and biotechnology platforms with GTBL’s fermentation expertise, large-scale manufacturing capabilities and portfolio.

With the transaction now complete, GTBL and MBJ will continue to operate as part of an expanded platform combining Japan-based biotechnology and fermentation capabilities with India-based manufacturing scale, supporting the company’s plans to strengthen its global CDMO presence.

Impact on the Chemical Market

The acquisition will accelerate GTBL’s transition towards becoming a fermentation-based, globally integrated CDMO. By combining MicroBiopharm’s biotechnology capabilities with GTBL’s manufacturing strengths in India, the company expects to build capabilities across several high-value areas. These include precision fermentation, enzyme-based bioconversion, APIs, advanced biologics, novel modalities, and scalable regulated manufacturing.

In addition to that, the combined platform will provide GTBL with a more diversified global revenue base and access to large pharmaceutical customers. The company also plans to leverage its India manufacturing cost advantage to expand margins.

Impact on the Biopharmaceuticals Market

The global biopharmaceuticals market size is calculated at USD 537.54 billion in 2025 and is predicted to increase from USD 616.02 billion in 2026 to approximately USD 1,983.73 billion by 2035, expanding at a CAGR of 13.95% from 2026 to 2035.

According to Precedence Research, the growing demand for personalized medicines, burgeoning biotechnology sector, and technological advancements drive the market. The biopharmaceuticals market is experiencing robust growth, driven by the high consumer demand for better treatment outcomes, advances in manufacturing technologies, and the shifting trend towards precision medicines. Key players are collaborating to deliver their products across diverse geographical locations. They obtain regulatory approval for their proprietary biopharmaceuticals from local authorities to market the drug in that particular country.

The rising R&D activities to develop innovative and effective therapies are projected to create lucrative growth opportunities for the growth of the biopharmaceutical market during the forecast period. The market has witnessed a rise in research and development activities by prominent biopharmaceutical market players to develop innovative and effective drugs. Additionally, the active role of regulatory authorities like EMA and FDA in monitoring and providing approvals for the various new drugs to treat a range of diseases in the biopharmaceutical industry is driving the market's growth.